Parkinson’s disease: dopaminergic nerve cell model is consistent with experimental finding of increased extracellular transport of α-synuclein

BackgroundParkinson’s disease is an age-related disease whose pathogenesis is not completely known. Animal models exist for investigating the disease but not all results can be easily transferred to humans. Therefore, mathematical or probabilistic models for the human disease are to be constructed in silico in order to predict specific processes within a cell, such as the dopamine metabolism and transport processes in a neuron.ResultsWe present a Systems Biology Markup Language (SBML) model of a whole dopaminergic nerve cell consisting of 139 reactions and 111 metabolites which includes, among others, the dopamine metabolism and transport, oxidative stress, aggregation of α-synuclein (αSYN), lysosomal and proteasomal degradation, and mitophagy. The predictive power of the model was investigated using flux balance analysis for the identification of steady model states. To this end, we performed six experiments: (i) investigation of the normal cell behavior, (ii) increase of O2, (iii) increase of ATP, (iv) influence of neurotoxins, (v) increase of αSYN in the cell, and (vi) increase of dopamine synthesis. The SBML model is available in the BioModels database with identifier MODEL1302200000.ConclusionIt is possible to simulate the normal behavior of an in vivo nerve cell with the developed model. We show that the model is sensitive for neurotoxins and oxidative stress. Further, an increased level of αSYN induces apoptosis and an increased flux of αSYN to the extracellular space was observed.

[1]  A. Letai,et al.  Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. , 2009, Human molecular genetics.

[2]  D. Standaert,et al.  LRRK2 Inhibition Attenuates Microglial Inflammatory Responses , 2012, The Journal of Neuroscience.

[3]  E. Alnemri.  HtrA2 and Parkinson's disease: think PINK? , 2007, Nature Cell Biology.

[4]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[5]  C. Chu,et al.  After the banquet , 2013, Autophagy.

[6]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[7]  J. Galvin.  Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra , 2006, Acta Neuropathologica.

[8]  Falk Schreiber,et al.  VANTED: A system for advanced data analysis and visualization in the context of biological networks , 2006, BMC Bioinformatics.

[9]  Armin Giese,et al.  Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.

[10]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[11]  H. Nijhout,et al.  Theoretical Biology and Medical Modelling Open Access Homeostatic Mechanisms in Dopamine Synthesis and Release: a Mathematical Model , 2022 .

[12]  S. Chung,et al.  Drug-Induced Parkinsonism , 2012, Journal of clinical neurology.

[13]  Andreas Zell,et al.  Use of support vector machines for disease risk prediction in genome‐wide association studies: Concerns and opportunities , 2012, Human mutation.

[14]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[15]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[16]  H. Büeler.  Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease , 2009, Experimental Neurology.

[17]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[18]  M. Beal,et al.  Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.

[19]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[20]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[21]  Wolfdieter Springer,et al.  Regulation of PINK1-Parkin-mediated mitophagy , 2011, Autophagy.

[22]  M. Beal,et al.  Parkinson's disease: a model dilemma , 2010, Nature.

[23]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[24]  J. Downward,et al.  The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 , 2007, Nature Cell Biology.

[25]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[26]  Melanie I. Stefan,et al.  BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models , 2010, BMC Systems Biology.

[27]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[28]  J. Schaack,et al.  Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture , 2002, Brain Research.

[29]  PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1 , 2007, PLoS biology.

[30]  Andreas Zell,et al.  Precise generation of systems biology models from KEGG pathways , 2013, BMC Systems Biology.

[31]  G. Stein,et al.  TRAP-1, the mitochondrial Hsp90 ☆ , 2012 .

[32]  Benedikt Westermann,et al.  Mitochondrial fusion and fission in cell life and death , 2010, Nature Reviews Molecular Cell Biology.

[33]  Y. Akao,et al.  Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease. , 2002, Neurotoxicology and teratology.

[34]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[35]  Andreas Zell,et al.  KEGGtranslator: visualizing and converting the KEGG PATHWAY database to various formats , 2011, Bioinform..

[36]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[37]  J. Nutt,et al.  Parkinson's disease , 2004, The Lancet.

[38]  E. Zamrini,et al.  Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.

[39]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[40]  K. Lim,et al.  Role of the ubiquitin proteasome system in Parkinson's disease , 2007, BMC Biochemistry.

[41]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[42]  B. Friguet.  Oxidized protein degradation and repair in ageing and oxidative stress , 2006, FEBS letters.

[43]  Alexander E. Kel,et al.  TRANSPATH®: an information resource for storing and visualizing signaling pathways and their pathological aberrations , 2005, Nucleic Acids Res..

[44]  G. Owens,et al.  Cell death in the nervous system. , 1997, The journal of investigative dermatology. Symposium proceedings.

[45]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[46]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[47]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[48]  M. LaVoie,et al.  The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax , 2012, Proceedings of the National Academy of Sciences.

[49]  北田 徹.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1999 .

[50]  R. Krüger,et al.  Reduced Basal Autophagy and Impaired Mitochondrial Dynamics Due to Loss of Parkinson's Disease-Associated Protein DJ-1 , 2010, PloS one.

[51]  T. Gasser,et al.  DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. , 2009, Free radical biology & medicine.

[52]  Anushya Muruganujan,et al.  PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification , 2003, Nucleic Acids Res..

[53]  R. Roth,et al.  Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease , 1997, Experimental Neurology.

[54]  Falk Schreiber,et al.  FBA-SimVis: interactive visualization of constraint-based metabolic models , 2009, Bioinform..

[55]  D. Calne,et al.  Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. , 2004, Brain : a journal of neurology.